CR20150147A - Polipéptidos que contienen fc con glicosilación alterada y función efectora reducida - Google Patents

Polipéptidos que contienen fc con glicosilación alterada y función efectora reducida

Info

Publication number
CR20150147A
CR20150147A CR20150147A CR20150147A CR20150147A CR 20150147 A CR20150147 A CR 20150147A CR 20150147 A CR20150147 A CR 20150147A CR 20150147 A CR20150147 A CR 20150147A CR 20150147 A CR20150147 A CR 20150147A
Authority
CR
Costa Rica
Prior art keywords
altered
glycosilation
polypeptides containing
effective function
reduced effective
Prior art date
Application number
CR20150147A
Other languages
English (en)
Spanish (es)
Inventor
Clark Pan
Huawei Qiu
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50278674&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20150147(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2012/003819 external-priority patent/WO2013037484A2/en
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of CR20150147A publication Critical patent/CR20150147A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CR20150147A 2012-09-12 2015-03-19 Polipéptidos que contienen fc con glicosilación alterada y función efectora reducida CR20150147A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2012/003819 WO2013037484A2 (en) 2011-09-12 2012-09-12 Anti-aplhabetatcr antibody
US201361776715P 2013-03-11 2013-03-11
PCT/US2013/059481 WO2014043361A1 (en) 2012-09-12 2013-09-12 Fc containing polypeptides with altered glycosylation and reduced effector function

Publications (1)

Publication Number Publication Date
CR20150147A true CR20150147A (es) 2015-05-29

Family

ID=50278674

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150147A CR20150147A (es) 2012-09-12 2015-03-19 Polipéptidos que contienen fc con glicosilación alterada y función efectora reducida

Country Status (34)

Country Link
EP (3) EP3366705B1 (enExample)
JP (1) JP6438397B2 (enExample)
KR (3) KR102426488B1 (enExample)
CN (2) CN104797601B (enExample)
AU (1) AU2013315499B2 (enExample)
CA (1) CA2884762C (enExample)
CL (1) CL2015000606A1 (enExample)
CR (1) CR20150147A (enExample)
CY (1) CY1120909T1 (enExample)
DK (2) DK2895513T3 (enExample)
DO (1) DOP2015000050A (enExample)
EA (2) EA202091166A1 (enExample)
EC (1) ECSP15014133A (enExample)
ES (2) ES2684549T3 (enExample)
FI (1) FI3366705T3 (enExample)
HR (2) HRP20230623T1 (enExample)
HU (2) HUE039337T2 (enExample)
IL (4) IL237640B (enExample)
LT (2) LT3366705T (enExample)
MA (1) MA37949B1 (enExample)
MX (2) MX366103B (enExample)
MY (1) MY170126A (enExample)
NZ (1) NZ705983A (enExample)
PE (1) PE20150650A1 (enExample)
PH (1) PH12015500528A1 (enExample)
PL (2) PL3366705T3 (enExample)
PT (2) PT2895513T (enExample)
RS (2) RS57748B1 (enExample)
SG (2) SG11201501521TA (enExample)
SI (2) SI2895513T1 (enExample)
TN (1) TN2015000085A1 (enExample)
UA (1) UA116995C2 (enExample)
WO (1) WO2014043361A1 (enExample)
ZA (1) ZA201501417B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
US9701753B2 (en) 2013-03-11 2017-07-11 Genzyme Corporation Hyperglycosylated binding polypeptides
AU2015231307B2 (en) * 2014-03-19 2021-01-28 Genzyme Corporation Site-specific glycoengineering of targeting moieties
AU2015243512B2 (en) 2014-04-08 2020-06-04 University Of Georgia Research Foundation Inc. Site-specific antibody-drug glycoconjugates and methods
CN113332449B (zh) * 2014-06-12 2023-12-22 石药集团巨石生物制药有限公司 酶法制备同质的抗体-药物缀合物
CN108025083B (zh) * 2014-10-09 2021-09-03 建新公司 糖工程化的抗体药物缀合物
TWI824372B (zh) 2015-10-12 2023-12-01 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
EP3222292A1 (en) 2016-03-03 2017-09-27 Heidelberg Pharma GmbH Amanitin conjugates
TW201815821A (zh) 2016-07-18 2018-05-01 美商再生元醫藥公司 抗茲卡病毒抗體及使用方法
SI3538554T1 (sl) 2016-11-08 2025-10-30 Regeneron Pharmaceuticals, Inc. Proteini, ki vežejo antigen, ki antagonizirajo leptinski receptor
WO2018107116A1 (en) * 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby
GB201717446D0 (en) 2017-10-24 2017-12-06 Evox Therapeutics Ltd Affinity purification of engineering extracellular vesicles
MX2020006508A (es) 2017-12-18 2020-09-17 Regeneron Pharma Moleculas de union a antigeno biespecificas que se unen al receptor de leptina y/o gp130, y metodos para el uso de estas.
US11608381B2 (en) 2018-04-06 2023-03-21 Regeneron Pharmaceuticals, Inc. Methods of treatment using a leptin receptor agonist antibody
JP1640846S (enExample) * 2018-10-16 2019-09-09
MA55134A (fr) 2018-11-21 2021-09-29 Regeneron Pharma Anticorps anti-staphylococcus et leurs utilisations
MA66057B2 (fr) 2018-12-21 2025-09-30 Regeneron Pharmaceuticals, Inc Analogues de rifamycine et conjugués anticorps-médicament de ceux-ci
MX2021008958A (es) 2019-02-01 2021-11-04 Regeneron Pharma Proteínas de unión a antígeno del receptor gamma anti-il2.
JP7607579B2 (ja) * 2019-03-27 2024-12-27 ティガティーエックス， インコーポレイテッド 工学的に操作されたＩｇＡ抗体および使用方法
CN120192414A (zh) 2019-04-03 2025-06-24 建新公司 具有降低的断裂的抗αβTCR结合多肽
AU2021268026A1 (en) 2020-05-08 2023-01-19 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
KR20230069969A (ko) 2020-09-15 2023-05-19 리제너론 파마슈티칼스 인코포레이티드 통증에 대한 lepr 아고니스트의 사용
KR20220052098A (ko) 2020-10-20 2022-04-27 주식회사 엘지에너지솔루션 마스킹 테이프를 이용한 전극 시편에 대한 물성 측정 시스템 및 이를 이용한 물성 측정 방법
KR102576252B1 (ko) * 2021-04-07 2023-09-11 아주대학교산학협력단 산화된 면역글로불린을 유효성분으로 포함하는 면역조절 기능 이상 관련 질환 예방 또는 치료용 약학적 조성물
WO2023069711A1 (en) * 2021-10-22 2023-04-27 Trustees Of Tufts College Fap-targeted neutron capture agents, and uses and formulations related thereto
CA3261203A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. COMPOSITIONS AND METHODS OF ADMINISTRATION MEDIATED BY THE TRANSFERRIN RECEPTOR (TFR) TO THE BRAIN AND MUSCLE
EP4561598A1 (en) 2022-07-29 2025-06-04 Regeneron Pharmaceuticals, Inc. Viral particles retargeted to transferrin receptor 1
CN120265655A (zh) 2022-07-29 2025-07-04 瑞泽恩制药公司 抗tfr：有效载荷融合物及其使用方法
WO2024098002A1 (en) 2022-11-04 2024-05-10 Regeneron Pharmaceuticals, Inc. Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
KR20250120451A (ko) 2022-11-14 2025-08-08 리제너론 파마슈티칼스 인코포레이티드 항-fgfr3 항체 및 항원 결합 단편 및 이의 사용 방법
JP2025538220A (ja) 2022-11-14 2025-11-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アストロサイトへの線維芽細胞増殖因子受容体３媒介送達のための組成物および方法
AU2024304472A1 (en) 2023-06-16 2026-01-08 Regeneron Pharmaceuticals, Inc. Cd40 x cd40 bispecific antigen-binding molecules and uses thereof
AU2024317508A1 (en) 2023-07-28 2026-01-29 Regeneron Pharmaceuticals, Inc. Anti-tfr: acid sphingomyelinase for treatment of acid sphingomyelinase deficiency
AU2024317483A1 (en) 2023-07-28 2026-01-29 Regeneron Pharmaceuticals, Inc. Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease
WO2025088546A1 (en) 2023-10-25 2025-05-01 Ablynx N.V. Fc domain variants with enhanced fc receptor binding
WO2025099632A1 (en) 2023-11-08 2025-05-15 Sanofi Cd25 based lysosomal degrader and uses thereof
WO2025160340A2 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
US20250242056A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
WO2025184603A2 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
EP4616869A1 (en) * 2024-03-15 2025-09-17 Oncomatryx Biopharma, S.L. Fap targeted antibody-drug conjugates

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
AU6873396A (en) 1995-10-16 1997-05-07 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
ATE386809T1 (de) 1996-08-02 2008-03-15 Bristol Myers Squibb Co Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
AU770555B2 (en) 1998-08-17 2004-02-26 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
CN1763097B (zh) 1999-01-15 2011-04-13 杰南技术公司 具有改变的效应功能的多肽变体
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2002002781A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
WO2002060919A2 (en) 2000-12-12 2002-08-08 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
US20040002587A1 (en) * 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CA2478011C (en) 2002-03-01 2013-05-21 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
CA2495251C (en) 2002-08-14 2018-03-06 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
EP1553975B8 (en) 2002-09-27 2023-04-12 Xencor, Inc. Optimized fc variants and methods for their generation
DE60334141D1 (de) 2002-10-15 2010-10-21 Facet Biotech Corp VERÄNDERUNG VON FcRn-BINDUNGSAFFINITÄTEN ODER VON SERUMHALBWERTSZEITEN VON ANTIKÖRPERN MITTELS MUTAGENESE
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
KR100758755B1 (ko) * 2003-06-12 2007-09-14 일라이 릴리 앤드 캄파니 Ｇｌｐ-1 유사체 융합 단백질
US8399618B2 (en) * 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
EP2385069A3 (en) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
EP1697520A2 (en) 2003-12-22 2006-09-06 Xencor, Inc. Fc polypeptides with novel fc ligand binding sites
US20080089892A1 (en) 2004-01-12 2008-04-17 Eli Lilly And Co. Fc Region Variants
WO2005092925A2 (en) 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
KR100863776B1 (ko) 2004-07-15 2008-10-16 젠코어 인코포레이티드 최적화된 Ｆｃ 변이체
AU2005289594B2 (en) * 2004-09-27 2012-02-02 Centocor, Inc. Srage mimetibody, compositions, methods and uses
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
JP2008537941A (ja) * 2005-03-31 2008-10-02 ゼンコー・インコーポレイテッド 最適化特性を有するＦｃ変異体
KR20080032026A (ko) * 2005-05-09 2008-04-14 글리카트 바이오테크놀로지 아게 개질된 Ｆｃ 영역을 갖고 Ｆｃ 수용체에 변형된 결합을하는 항원 결합 분자
WO2006130834A2 (en) 2005-05-31 2006-12-07 Board Of Regents, The University Of Texas System IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF
EP1896071B1 (en) 2005-06-30 2015-04-29 Janssen Biotech, Inc. Methods and compositions with enhanced therapeutic activity
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8460362B2 (en) 2006-07-20 2013-06-11 Orbusneich Medical, Inc. Bioabsorbable polymeric medical device
JP5357778B2 (ja) * 2007-01-23 2013-12-04 ゼンコー・インコーポレイテッド 最適化ｃｄ４０抗体および前記を使用する方法
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EP2268807A2 (en) * 2008-04-21 2011-01-05 Novo Nordisk A/S Hyperglycosylated human coagulation factor ix
RU2608504C2 (ru) * 2011-02-25 2017-01-18 Чугаи Сейяку Кабусики Кайся FcγRIIb-СПЕЦИФИЧНОЕ Fc-АНТИТЕЛО
TWI622597B (zh) 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
UY34317A (es) * 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß

Also Published As

Publication number Publication date
SI3366705T1 (sl) 2023-08-31
CA2884762C (en) 2022-07-19
KR102426488B1 (ko) 2022-07-28
MX366103B (es) 2019-06-27
HRP20230623T1 (hr) 2023-09-29
IL271027B (en) 2020-09-30
IL237640B (en) 2019-12-31
MX2015003234A (es) 2015-11-16
KR102185151B1 (ko) 2020-12-01
KR20220110855A (ko) 2022-08-09
PL2895513T3 (pl) 2018-11-30
IL271027A (en) 2020-01-30
EP3366705A1 (en) 2018-08-29
AU2013315499B2 (en) 2018-08-09
NZ705983A (en) 2018-06-29
RS57748B1 (sr) 2018-12-31
PH12015500528A1 (en) 2015-05-04
IL276866B (en) 2021-10-31
FI3366705T3 (fi) 2023-07-28
MY170126A (en) 2019-07-05
DK3366705T5 (da) 2024-09-30
PT3366705T (pt) 2023-07-19
WO2014043361A1 (en) 2014-03-20
MX2019007753A (es) 2019-09-09
UA116995C2 (uk) 2018-06-11
EP3366705B1 (en) 2023-05-03
PT2895513T (pt) 2018-10-08
EP2895513A1 (en) 2015-07-22
HK1207389A1 (en) 2016-01-29
SG10201701831VA (en) 2017-05-30
EA202091166A1 (ru) 2021-04-30
CA2884762A1 (en) 2014-03-20
HUE039337T2 (hu) 2018-12-28
AU2013315499A1 (en) 2015-04-02
CN104797601A (zh) 2015-07-22
RS64317B1 (sr) 2023-08-31
TN2015000085A1 (en) 2016-06-29
ZA201501417B (en) 2016-12-21
EP4223783A2 (en) 2023-08-09
BR112015005352A2 (pt) 2017-08-08
DK2895513T3 (en) 2018-09-03
KR20150054931A (ko) 2015-05-20
HUE062876T2 (hu) 2023-12-28
CN104797601B (zh) 2019-08-30
SI2895513T1 (sl) 2018-11-30
LT2895513T (lt) 2018-09-10
DOP2015000050A (es) 2015-04-15
JP6438397B2 (ja) 2018-12-12
DK3366705T3 (da) 2023-07-31
KR20200136044A (ko) 2020-12-04
ES2950509T3 (es) 2023-10-10
EA201590545A1 (ru) 2015-08-31
IL286766A (en) 2021-10-31
ES2684549T3 (es) 2018-10-03
PE20150650A1 (es) 2015-05-26
MA37949A1 (fr) 2016-05-31
IL237640A0 (en) 2015-04-30
IL276866A (en) 2020-10-29
SG11201501521TA (en) 2015-03-30
PL3366705T3 (pl) 2023-09-18
EP4223783A3 (en) 2023-11-15
ECSP15014133A (es) 2017-02-24
CY1120909T1 (el) 2019-12-11
CN110590953A (zh) 2019-12-20
EA035987B1 (ru) 2020-09-09
LT3366705T (lt) 2023-07-25
EP2895513B1 (en) 2018-05-23
HRP20181354T1 (hr) 2018-10-19
CL2015000606A1 (es) 2015-11-13
MA37949B1 (fr) 2017-07-31
JP2015533490A (ja) 2015-11-26

Similar Documents

Publication Publication Date Title
CR20150147A (es) Polipéptidos que contienen fc con glicosilación alterada y función efectora reducida
HUS2100038I1 (hu) Anti-CD20 antitest készítmények
CY1121390T1 (el) Πυρρολοβενζοδιαζεπινες και συζευγματα αυτων
CY1122101T1 (el) Τροποποιημενα πολυπεπτιδια ρελαξινης και χρησεις αυτων
CO2019005966A2 (es) Esteroides y conjugados de proteínas de los mismos
MX2019003214A (es) Formulaciones de proteina de inmunoglobulina del dominio variable dual estable.
UY37278A (es) Anticuerpos anti-b7-h3 y conjugados de fármaco y anticuerpos
MX384366B (es) Conjugados enlazadores auto-estabilizantes.
EP3081980A4 (en) Optical scan device, illumination device, projection device, and optical element
BR112015010436A2 (pt) Anticorpos anti-notch3 e conjugados anticorpo-fármaco
GEP20227398B (en) Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof
KR101820865B9 (ko) 유기광전자소자용 재료, 이를 포함하는 유기발광소자 및 상기 유기발광소자를 포함하는 표시장치
DK3431497T3 (da) Spaltede inteiner, konjugater og anvendelser deraf
CR20150049A (es) Anticuerpos e inmunoconjugados anti-cd79b
EP2910554A4 (en) BENZINDOLOCARBAZOLE DERIVATIVE MATERIAL MANUFACTURED THEREFOR FOR A LIGHT-EMITTING ELEMENT AND LIGHT-EMITTING ELEMENT
IL205705A (en) Anti-influenza antibodies, compositions comprising the same and uses thereof
MX2015004420A (es) Conjugados del anticuerpo pirrolobenzodiazepina - anti-cd22.
UY4151Q (es) Vincha con auriculares
DK3054992T3 (da) Protein-polymer-lægemiddelkonjugater
BR112014029403A2 (pt) conjugados, anticorpo e formulação farmacêutica
CL2015003481A1 (es) Conjugados de anticuerpo fármaco
EP2775328A4 (en) REFLECTIVE OPTICAL FILM AND OPTICAL REFLECTOR THEREWITH
UY35463A (es) Formulaciones de polipéptido fc-factor ix.
EP3006535A4 (en) Base polymer for hot-melt adhesive agent, and hot-melt adhesive agent
EP3775186A4 (en) ECTONUCLEOTIDE PYROPHOSPHATE-PHOSPHODIESTERASE (ENPP) CONJUGATES AND THEIR USES